Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087069 | 0.82 | DRD2 (0.47) | NAMPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL28775447 | 0.81 | MC4R (0.50) | NAMPT | |
| SCHEMBL9387391 | 0.78 | CYP2D6 (0.47) | NAMPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22875064 | 0.78 | SIGMAR1 (0.48) | NAMPTKMT2AHDAC4OPRM1 | |
| SCHEMBL8129232 | 0.76 | MEN1 (0.53) | NAMPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14544155 | 0.75 | NAMPT (0.53) | NAMPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3079800 | 0.75 | MEN1 (0.48) | NAMPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL10696821 | 0.75 | MMP2 (0.52) | NAMPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL16795975 | 0.74 | KDM4E (0.52) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL9074062 | 0.74 | KDM4E (0.54) | NAMPTKDM4EALDH1A1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945639-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | Pfizer Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | PFIZER LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| WO-2007052124-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVE | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179175-A1 | Tetrahydronaphthyridine Derivative | HRH4, HRH3, HRH1 | NAMPT 4/4885KDM4E 2718/4885ALDH1A1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.